- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.

Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy
- Share
- Tweet
- Share on Facebook
- Share


Poster title: Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy
Presented at BSH 2024
Pamart et al
Related Articles
- Blog
The evolution, challenges, and hope for the future of intensive care: an interview with Dr. Andrew Retter, Consultant in Critical Care, ECMO and Thrombosis and Clinical Lead at one of London’s prominent hospitals and Volition CMO.
- Presentation
Volition Corporate Deck. Discover how Volition is transforming diagnostics with affordable, early-detection and treatment-monitoring tests.
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields